lanadelumab (Takhzyro)
Jump to navigation
Jump to search
Indications
Dosage
- twice monthly SQ
Mechanism of action
- monoclonal antibody inhibitor of kallikrein
More general terms
References
- ↑ Amrol DJ Novel Medication for Hereditary Angioedema NEJM Journal Watch. Feb 23, 2017 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Banerji A, Busse P, Shennak M et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 2017 Feb 23; 376:717. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28225674 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1605767